Protect

Protect Therapeutics is a preclinical-stage biotechnology company focused on developing first-in-class small molecule therapies for neurodegenerative diseases and acute brain injuries. The company's primary approach involves targeting the cofilin-actin pathway to prevent the formation of cofilin-actin rods, which are known to disrupt synaptic function and contribute to neuronal loss in conditions like Alzheimer's disease. By inhibiting the pathological activation of cofilin, Protect Therapeutics aims to preserve cognitive function and slow disease progression. Their lead research programs are currently exploring the efficacy of these inhibitors in models of Alzheimer's and traumatic brain injury.